Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Utility and limitations of 18F-fluciclovine PET for biopsy targeting in a nonenhancing diffuse glioma with a gliomatosis cerebri–like growth pattern: illustrative case. Local targets link to admitted publications; unresolved targets remain external evidence.
Imaging diagnosis of adult-type diffuse gliomas in the era of WHO CNS5 and cIMPACT-NOW updates 8-11: a narrative review
2026 · External reference
Comparative evaluation of transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid and L-[methyl-11C]methionine in human glioma cell lines
2013 · External reference
Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells
2012 · External reference
Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings
2015 · External reference
Diagnostic performance and safety of positron emission tomography using 18F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial
2017 · External reference
[18F]Fluciclovine PET discrimination between high- and low-grade gliomas
2018 · External reference
18F-FACBC PET/MRI in Diagnostic assessment and neurosurgery of gliomas
2019 · External reference
Revisiting gliomatosis cerebri in adult-type diffuse gliomas: a comprehensive imaging, genomic and clinical analysis
2024 · External reference
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · External reference
cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC)
2018 · External reference
Clinical and molecular characteristics and prognostic factors of diffuse astrocytoma, IDH-wildtype, not elsewhere classified
2025 · External reference
All-in-one bimodal DNA and RNA next-generation sequencing panel for integrative diagnosis of glioma
2024 · External reference
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma
2021 · External reference
Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
2022 · External reference
PDGFRA, KIT, and KDR gene amplification in glioblastoma: heterogeneity and clinical significance
2023 · External reference
Spatial concordance of DNA methylation classification in diffuse glioma
2021 · External reference
Investigational PET tracers in neuro-oncology—what’s on the horizon? A report of the PET/RANO group
2022 · External reference
F-Fluciclovine (18F-FACBC) PET/CT or PET/MRI in gliomas/glioblastomas
2020 · External reference
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
2016 · External reference
H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers
2017 · External reference
